Pafolacianine for Ovarian Cancer Detection During Surgery

home / approval-alert / pafolacianine-for-ovarian-cancer-detection-during-surgery
Pafolacianine for Ovarian Cancer Detection During Surgery

Pafolacianine for Ovarian Cancer Detection During Surgery

In November 2021, the FDA approved pafolacianine for use as an imaging drug for identifying lesions in patients with ovarian cancer during surgery.

Articles
A Look Behind Development of Pafolacianine for Tumor Detection During Ovarian Cancer Surgery

A Look Behind Development of Pafolacianine for Tumor Detection During Ovarian Cancer Surgery

December 21st 2021

Philip S. Low, PhD, discusses the obstacles he overcame while creating pafolacianine and what other cancers he hopes will be improved with the use of this agent.

Imaging drug imaging drug pafolacianine was approved by the FDA to detect ovarian cancer lesions in patients during surgery.

Imaging Drug Pafolacianine Approved by FDA for Detection of Ovarian Cancer During Surgery

November 29th 2021

Imaging drug pafolacianine was approved by the FDA to detect ovarian cancer lesions in patients during surgery.

View More >>
Videos
Medical World News® Inside the Practice: Phillip Low, PhD, on the Development and Approval of Pafolacianine

Medical World News® Inside the Practice: Phillip Low, PhD, on the Development and Approval of Pafolacianine

January 30th 2022

CancerNetwork® spoke with Phillip Low, PhD, about the development and FDA approval of pafolacianine.